NFKB1 and acute myeloid leukemia: Accordingly, treatment with Verteporfin, an FDA-approved photosensitizer, reduced AML development in vivo, through upregulation of RelB and p52, members of NF-κB alternative pathway, mimicking the effects of NIK stabilization [106] (Figure 2).